ImmunityBio Inc [IBRX] stock is trading at $6.17, up 15.98%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IBRX shares have gain 73.80% over the last week, with a monthly amount glided 57.00%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
ImmunityBio Inc [NASDAQ: IBRX] stock has seen the most recent analyst activity on May 12, 2023, when Piper Sandler downgraded its rating to a Neutral and also revised its price target to $4 from $10. Previously, Jefferies started tracking the stock with Buy rating on August 03, 2022, and set its price target to $8.
ImmunityBio Inc [IBRX] stock has fluctuated between $1.62 and $10.53 over the past year. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. ImmunityBio Inc [NASDAQ: IBRX] shares were valued at $6.17 at the most recent close of the market. An investor can expect a potential return of 29.66% based on the average IBRX price forecast.
Analyzing the IBRX fundamentals
ImmunityBio Inc [NASDAQ:IBRX] reported sales of 1.31M for the trailing twelve months, which represents a growth of 2453.66%. Gross Profit Margin for this corporation currently stands at -12.85% with Operating Profit Margin at -274.59%, Pretax Profit Margin comes in at -456.98%, and Net Profit Margin reading is -456.92%. To continue investigating profitability, this company’s Return on Assets is posted at -1.35, Equity is 1.0 and Total Capital is -0.94. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.61 points at the first support level, and at 5.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.77, and for the 2nd resistance point, it is at 7.38.
Ratios To Look Out For
For context, ImmunityBio Inc’s Current Ratio is 3.91. Further, the Quick Ratio stands at 3.88, while the Cash Ratio is 2.09. Considering the valuation of this stock, the price to sales ratio is 3280.60.
